Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Executive summary

Burden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

4 evidence topics · 33 sources

Summary: incidence, prevalence, recurrence, and survival

In the United States in 2026, an estimated 321,910 new cases of invasive breast cancer will be diagnosed in women and 2,670 in men, and an estimated 42,670 breast cancer deaths (42,140 in women, 530 in men) will occur. In SEER data, the HR+/HER2- subtype had an age-adjusted rate of 92.9 new cases per 100,000 women (2019 to 2023 cases) and accounted for 70% of female breast cancer cases; 6% of female breast cancer cases were distant stage at diagnosis. Of an estimated 50,344 new diagnoses of metastatic breast cancer in 2013, 12,966 (26%) were de novo and 37,378 (74%) were recurrences. A second model estimated 46,666 new metastatic female breast cancer cases (de novo and recurrence) in 2018 and projected 52,126 in 2025. In a separate analysis, breast cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years, and the risk of distant recurrence ranged from 13% with T1N0 disease to 41% with T2N4–9 disease.

An estimated 138,622 women were living with metastatic breast cancer in the United States in 2013, and 154,794 were projected by January 1, 2017. The second model estimated 140,230 individuals living with metastatic female breast cancer on January 1, 2018 and projected 169,347 on January 1, 2025. A separate estimate found that 61% of women living with metastatic breast cancer were originally diagnosed with stage I to III disease. Five-year relative survival for HR+/HER2- female breast cancer was 100.0% for localized, 91.1% for regional, and 38.1% for distant stage, compared with 33.8% for distant-stage female breast cancer of all subtypes. The female breast cancer death rate was 18.9 per 100,000 women per year (2020 to 2024, age-adjusted). In HR+/HER2- metastatic breast cancer, median breast cancer-specific survival was 39 months in the post-2015 group and 35 months in the pre-2015 group (hazard ratio 0.896), with 48-month rates of 44.5% and 38.5%. Treatment of metastatic disease is “palliative in intent”.

Summary: endocrine resistance, ESR1 mutations, and outcomes after a first-line CDK4/6 inhibitor

Most HR-positive breast cancers that benefit from first-line endocrine therapy eventually become endocrine-resistant, and second-line endocrine monotherapy has a median progression-free survival of 2 to 6 months, compared with 1 to 4 years for first-line endocrine therapy. About 50% of endocrine resistance cases are associated with an ESR1 mutation. Approximately 20% to 40% of patients who have received aromatase inhibition for metastatic breast cancer have ESR1 mutations, which occur “almost exclusively after AI in the metastatic setting”; in one cohort, ESR1 mutation prevalence was 5.8% (3 of 52) among participants first exposed to an aromatase inhibitor in the adjuvant setting and 36.4% (16 of 44) among those first exposed in the metastatic setting. In real-world genomic testing, ESR1 mutation prevalence in tissue biopsies collected within 60 days of the start of first-, second-, and third-line therapy was 8.1% (175 of 2,154), 27.1% (73 of 269), and 33.3% (72 of 216); in liquid biopsies with a tumor fraction of 1% or more it was 17.5% in first line and 59% in third line. A PI3K/AKT pathway alteration was present in 55.1%, 48.3%, and 54.6% of tissue biopsies in the same three lines, and both an ESR1 mutation and a PI3K/AKT pathway alteration in 4.4%, 8.2%, and 17.1%.

In BOLERO-2, 156 of 541 evaluable participants (28.8%) had an ESR1 D538G and/or Y537S mutation; overall survival was 32.1 months with wild-type ESR1, 25.99 months with D538G, 19.98 months with Y537S, and 15.15 months with both mutations. Loss of ER expression occurs in approximately 10% of endocrine-resistant breast cancers, and one analysis reported that 60% of endocrine-resistant metastatic breast cancers lacked known somatic drivers of resistance. In a cohort of 839 participants who received a second-line therapy after progression on a first-line CDK4/6 inhibitor, median real-world progression-free survival was 3.71 months with chemotherapy, 3.25 months with fulvestrant monotherapy, 3.32 months with everolimus, and 8.25 months with a second-line CDK4/6 inhibitor. A systematic review of 18 studies of second-line treatment after a first-line CDK4/6 inhibitor calculated a weighted average median real-world progression-free survival of 3.9 months for single-agent endocrine therapy, 3.6 months for an mTOR inhibitor with or without endocrine therapy, and 6.1 months for chemotherapy; no study reported disaggregated outcomes in the third-line setting or beyond.

Summary: humanistic burden and health-related quality of life

In a cross-sectional survey of physicians and their patients with HR+/HER2- metastatic breast cancer in Europe and the United States (August 2022 to February 2023), 298 physicians provided data on 1,642 participants, of whom 321 self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects; physicians reported bone pain (30.3%) as the most frequent symptom and estimated that 55.1% of participants experienced no side effects, and low patient-physician concordance was “associated with worse HRQoL”. In a study of 739 participants and 173 oncologists, the mean health utility index was 0.73 overall; it was 0.62 with visceral and bone metastases, 0.68 with bone-only metastases, and 0.78 with visceral-only metastases, and 0.81, 0.63, and 0.40 with mild, moderate, and severe worst pain. Moderate or extreme anxiety/depression was reported by 66.7% of participants receiving chemotherapy and 53.1% of those receiving endocrine therapy. In a standard gamble study of 100 members of the general public, stable disease on treatment had a utility of 0.72, with a gain of 0.07 after a treatment response, a decline of 0.27 for disease progression, and declines of 0.10 to 0.15 for toxicities.

Among 152 participants in the VIRGO observational study receiving first-line hormonal therapy or chemotherapy and/or targeted therapy for locally recurrent or metastatic breast cancer, the most common severe symptoms were of moderate-to-severe intensity in 38.8% to 52.0%, mean daily activity impairment was 30%, and work productivity impairment ranged from 20% to 40% among 58 employed participants. Average total time spent on health care ranged from 7% to 10% of all days in the first 3 months of treatment, depending on treatment. In a survey of 345 informal caregivers of people living with metastatic breast cancer in the United States, United Kingdom, and Germany, one in three changed work status after the onset of caregiving: 12% reduced working hours, 13% stopped working, and 8% increased working hours.

Summary: economic burden, family impact, and diagnostic testing costs

In one analysis, 3,203 participants received first-line, 2,194 second-line, and 1,242 third-line therapy for metastatic breast cancer; mean total healthcare costs per patient per month in the first, second, and third line were $6,521, $4,440, and $4,555 among those receiving endocrine therapy and $16,842, $12,868, and $16,129 among those receiving chemotherapy. Among 5,563 eligible participants in a second analysis, average monthly all-cause costs were $14,424 per patient, and 12-month indirect costs for short-term disability were $10,397 in participants with metastatic breast cancer, compared with $394 in matched noncancer participants. Using Medicare prices, the mean total per-patient treatment and supportive care drug cost for HR-positive, ERBB2-negative metastatic breast cancer was $104,774, and annual costs in year 1 for this subtype increased from $12,986 in 2011 to $80,563 in 2019. Among 5,709 participants with metastatic breast cancer, 56.8% had evidence of disease progression over 12 months, and per-patient-per-month costs were almost twice as high among progressors as among nonprogressors. Annualized cancer-attributable costs of medical care (Medicare Parts A and B) for breast cancer diagnosed at distant stage were $67.4 thousand in the initial phase, $22.3 thousand in the continuing phase, and $91.9 thousand in the end-of-life phase (2019 US dollars). Among 3,878 females in another analysis, the 18.5% who met end-of-life criteria had 6-month total healthcare costs of $72,112, compared with $17,137. Prevalence of metastatic breast cancer was projected to reach 246,194 cases in 2030, an increase of 54.8% from 158,997 in 2015, with total medical and productivity costs increasing from $63.4 billion in 2015 to $152.4 billion in 2030.

In the MarketScan Health and Productivity Management database (2005-2009), families of patients with metastatic breast cancer incurred 39.7% (p = 0.06) higher indirect costs than families of patients with early breast cancer. In a survey of 1,054 young adult women with metastatic cancer who responded from 41 states, 30% were uninsured, and uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio 2.38). Medicare pays $5,000.00 for Guardant360 CDx and $3,500.00 for FoundationOne Liquid CDx during the new Advanced Diagnostic Laboratory Test initial period. In one analysis, testing rates were approximately 32% at second line and 25% at third line across subgroups.